Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7542634

O=C(/C=C/c1ccc(Cl)s1)NC1CCN(CCNc2ccncc2)C1=O.O=C(O)C(F)(F)F

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
F10 P00742 17/20 0.37
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
F2 P00734 1/20 0.31
KLKB1 P03952 1/20 0.31
GPR6 P46095 1/20 0.31
TEAD1 P28347 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7378726 1.00 F10 (0.37) F10CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7537562 0.78 F10 (0.56) F10F2KLKB1
Trifluoroacetic Acid SCHEMBL7369139 0.78 F10 (0.37) F10CYP3A4CYP2D6CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL7537097 0.78 F10 (0.37) F10CYP3A4CYP2D6CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL7376191 0.74 F10 (0.34) F10CYP3A4CYP2D6CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL7536971 0.74 F10 (0.34) F10CYP3A4CYP2D6CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL7540066 0.73 F10 (0.42) F10
Trifluoroacetic Acid SCHEMBL7539307 0.73 F10 (0.42) F10
Trifluoroacetic Acid SCHEMBL7370017 0.73 DPP4 (0.38) F10CYP2D6CYP2C9F2GPR6
Trifluoroacetic Acid SCHEMBL7921647 0.73 DPP4 (0.38) F10CYP2D6CYP2C9F2GPR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-01-31 US claimed
US-6281227-B1 INHIBITORS OF THE ACTIVITY OF FACTOR XA. AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-08-28 US claimed
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds AVENTIS PHARMACEUTICALS PRODUCTS INC. 2002-01-31 US disclosed
US-6281227-B1 INHIBITORS OF THE ACTIVITY OF FACTOR XA. AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013310-A1 Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds STS, ARSA, F12 F10 20/4885CYP3A4 745/4885CYP2D6 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.